	US 11,788,090 B2
	Prevention and/or treatment of inflammatory skin disease
Luba Milena Pardo Cortes, Rotterdam (NL); Rebecca Susan Ginger, Loughborough (GB); David Andrew Gunn, St Neots (GB); Tamarius Edmond Christoffel Nijsten, Antwerp (BE); Martijn Gerard Hendrik Sanders, Rotterdam (NL); and Adrian Michael Smith, Corby (GB)
Assigned to CONOPCO, INC., Englewood Cliffs, NJ (US)
Appl. No. 16/611,847
Filed by Conopco, Inc., Englewood Cliffs, NJ (US)
PCT Filed May 3, 2018, PCT No. PCT/EP2018/061414 § 371(c)(1), (2) Date Nov. 7, 2019, PCT Pub. No. WO2018/206409, PCT Pub. Date Nov. 15, 2018.
Claims priority of application No. 17169956 (EP), filed on May 8, 2017.
Prior Publication US 2020/0063139 A1, Feb. 27, 2020
Int. Cl. C12N 15/113 (2010.01); A61K 8/04 (2006.01); A61Q 5/00 (2006.01); A61Q 5/02 (2006.01); A61Q 5/12 (2006.01); C12Q 1/48 (2006.01); G01N 33/68 (2006.01)

CPC C12N 15/1137 (2013.01) [A61K 8/042 (2013.01); A61Q 5/006 (2013.01); A61Q 5/02 (2013.01); A61Q 5/12 (2013.01); C12Q 1/485 (2013.01); C12Y 207/11001 (2013.01); G01N 33/6881 (2013.01); C12N 2310/14 (2013.01); G01N 2500/04 (2013.01)]

19 Claims

1. A method of treating an inflammatory skin condition in a mammalian subject that has a bacterial skin infection, the method comprising administering to the mammalian subject an effective dose of a short interfering RNA molecule that down-regulates the expression of a MAST4 gene.